To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
InteRNA and Radboud University to Develop microRNA-based Therapeutics for Prostate Cancer
Read time: Less than a minute
InteRNA Technologies B.V.
and
Radboud University Nijmegen Medical Centre
have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer.
Under the research collaboration with Professor Jack Schalken (Laboratory of Experimental Urology), InteRNA's lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer.
"We are very excited about this collaboration with professor Schalken, a renowned investigator in the prostate cancer field, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of prostate cancer," said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.
"Through the collaboration with InteRNA we gain access to a unique functional tool to identify microRNAs that are implicated in prostate carcinogenesis. Thus it is a truly symbiotic public-private partnership!" said professor Jack Schalken of Radboud UNMC.
Under the research collaboration with Professor Jack Schalken (Laboratory of Experimental Urology), InteRNA's lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer.
"We are very excited about this collaboration with professor Schalken, a renowned investigator in the prostate cancer field, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of prostate cancer," said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.
"Through the collaboration with InteRNA we gain access to a unique functional tool to identify microRNAs that are implicated in prostate carcinogenesis. Thus it is a truly symbiotic public-private partnership!" said professor Jack Schalken of Radboud UNMC.
